MSTQX
Price
$14.47
Change
-$0.11 (-0.75%)
Updated
Nov 14 closing price
RWMEX
Price
$64.49
Change
-$0.38 (-0.59%)
Updated
Nov 14 closing price
Ad is loading...

MSTQX vs RWMEX

Header iconMSTQX vs RWMEX Comparison
Open Charts MSTQX vs RWMEXBanner chart's image
Morningstar US Equity
Price$14.47
Change-$0.11 (-0.75%)
VolumeN/A
CapitalizationN/A
American Funds Washington Mutual R4
Price$64.49
Change-$0.38 (-0.59%)
VolumeN/A
CapitalizationN/A
MSTQX vs RWMEX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MSTQX vs. RWMEX commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MSTQX is a Buy and RWMEX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RWMEX has more cash in the bank: 194B vs. MSTQX (1.76B). RWMEX pays higher dividends than MSTQX: RWMEX (1.45) vs MSTQX (0.85). MSTQX was incepted earlier than RWMEX: MSTQX (6 years) vs RWMEX (23 years). MSTQX is a more actively managed with annual turnover of: 53.00 vs. RWMEX (30.00). MSTQX has a lower initial minimum investment than RWMEX: MSTQX (0) vs RWMEX (250). MSTQX annual gain was more profitable for investors over the last year : 28.00 vs. RWMEX (19.54). MSTQX (39.49) and RWMEX (39.34) have equivalent 5 years return.
MSTQXRWMEXMSTQX / RWMEX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years23 years-
Gain YTD22.83114.675156%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets1.76B194B1%
Annual Yield % from dividends0.851.4559%
Returns for 1 year28.0019.54143%
Returns for 3 years-2.1411.51-19%
Returns for 5 years39.4939.34100%
Returns for 10 yearsN/A58.73-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GTN4.790.39
+8.86%
Gray Television
FJTSF17.650.60
+3.52%
Fujitsu Ltd.
FUJHY7.830.05
+0.59%
Subaru Corporation
FOR29.610.09
+0.30%
Forestar Group
ACRS2.18-0.26
-10.66%
Aclaris Therapeutics